Skip to content
Enough Ventures
MenuClose

Capital meets conscience.

We help researchers and founders find a first market for a discovery and decide whether to license it or build a company.

Discuss your project
A presenter lifts a pair of smart glasses overhead, showing the display mounted on the frame.

Selected work

View all projects

PedTrak

Medical device

The full bench setup with sensors, two evaluation boards, a wired display and a tablet.

PedTrak

Nurses founded PedTrak to help clinicians track a pulse in an arm or leg. Our managing partner brought product and commercialization experience to the prototype team.

Radion Robotics

Nuclear medicine

A cluster of pale encapsulated particles beside a ruler marked in centimetres.

Radion Robotics

These iodide capsules come from research at Brazil’s Institute of Nuclear Engineering. Our managing partner leads commercialization of Radion’s radiopharmaceutical production technology.

Limis

Industrial software

An operator in a white hard hat uses a tablet beside industrial piping.

Limis

Limis turns an operator’s field readings into a plant record. Our managing partner helped the team scope how manufacturers could test the software on site.

LifeLensAR

Care documentation

A presenter lifts a pair of smart glasses overhead, showing the display mounted on the frame.

LifeLensAR

A nurse could dictate a bedside observation through smart glasses and review the chart entry. Our managing partner co-founded and led LifeLensAR before its acquisition in 2025.

Where we focus

Deep tech

Lab robotics, advanced materials and tools for scientific discovery.

Nuclear innovation

Medical isotopes and the systems that produce and handle them safely.

Social impact

Safer workplaces and wider access to care, with a way to measure who benefits.

How we choose our work

Who is better off if this works, and can that be shown?

From the isotope chart to the clinic.

Doctors use technetium-99m for diagnostic imaging and lutetium-177 for targeted cancer therapy.

Each block is one isotope. Taller blocks have more steps along the chart’s modeled decay path.

  • Found in nature
  • Neutron-rich
  • Proton-rich
  • Heavy, sheds alpha particles
Isotopes on the chart
3,352
Found in nature
288
Elements represented
118
Explore an isotope up close

Inside the nucleus

Each sphere represents one proton or neutron. The smaller nuclei contain fewer particles.

Actinium-225

89 protons, 136 neutrons. Targeted alpha therapy.

Who we work with

Most projects start with a researcher or founder asking who could put a discovery to use.

You have validated science and no clear route to market. We help you choose a license, a spinout or a partnership, then build it with you.

  • A plain read on commercial potential before more is spent on protection
  • Help choosing between a license, a spinout and a partnership
  • A commercialization plan your technology transfer team can work with
  • Introductions to operators and investors once the case is ready

What we do for researchers

  • Researchers and institutions

    You have validated science and no clear route to market. We help you choose a license, a spinout or a partnership, then build it with you.

    What we do for researchers
  • Founders

    You are building on hard science and need commercial proof, partners and capital. We work beside you from formation through early financing.

    What we do for founders
  • Investors

    Family offices and funds that want a technically grounded view of deep-tech and nuclear work. Conversations are private.

    How VentureIP works
  • Companies, agencies and foundations

    Bring a research, deployment or market-access question that someone in our network can help you test.

    How the network works

How research reaches the market

The first decision is whether to form a company, license the technology or develop it with a partner.

  1. Step 1

    Assess

    You leave withA technical and IP readout you can act on.

  2. Step 2

    Position

    You leave withA chosen route to market and the reasons for it.

  3. Step 3

    Build

    You leave withA company, a license or a partnership with a plan behind it.

  4. Step 4

    Prepare for funding

    You leave withIntroductions made when the case is ready, not before.

How each step worksStep 1 runs through VentureIP

Who we bring to the table

Explore the network
The Enough Ventures hub connects to research, commercialization and investment partners.
Enough Ventures

Research

What still needs proof?

University researchers, research institutes and technical experts help choose the experiment that would settle an open question.

See how VentureIP reviews evidence

Commercialization

Who would use it first?

Operators, corporate partners and technology transfer teams help define a first use and what a pilot would need to prove.

See the Xelios pilot plan

Investment

What would the next round fund?

Partner funds, family offices and strategic investors weigh the cost of the next milestone and the evidence behind it.

How we work with investors
VentureIP
Technical and patent review helps a team decide which route to market is worth pursuing.
Arkus Raise
A private workspace for organizing the materials a founder will share with prospective investors.

The partners

  • Chandler J. Lewis

    Managing Partner

    Seattle and São Paulo

    Thesis, commercialization strategy, nuclear and deep-tech partnerships

  • Krisztina Kapuvári

    General Partner and Co-Founder

    United Kingdom and Europe

    Founder support, ecosystem partnerships, social impact

  • Mike Lee

    General Partner and Co-Founder

CNEN
Chandler J. Lewis is an Innovation and Commercialization Fellow at Brazil's National Nuclear Energy Commission.
NASA
Chandler worked at NASA and co-founded LifeLensAR, which developed voice charting for nurses.
100+
Businesses Krisztina Kapuvári helped launch across Francophone West Africa as co-founder of theSPACE NGO.
5
Our partners work across North America, Latin America, Europe, Africa and Oceania.

Meet the partners

What are you working on?

Tell us what you’ve tested and where you could use a partner.